The Tim-3 pathway is a target for anticancer immunotherapy due to its expression on both non-functional CD8+ T cells and Tregs—two main immune cell groups that suppress the immune activity in tumour tissue [163] and has exhibited remarkable results in preclinical cancer models. Here, HAVCR2 is linked to neoplasm.